We are excited to be in Madrid for EBMT 2026 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible. Learn more about our scientific symposium and abstracts below.
CAR T IN DLBCL:
Welcome and introduction
Chair: Dr Anna Sureda
Institut Català d’Oncologia, Hospital Duran I Reynals, Barcelona, Spain
Overcoming misconceptions for better patient care
Misconception #1:
My patient isn’t the ‘right’ patient for CAR T
Dr Anna Sureda
Institut Català d’Oncologia, Hospital Duran i Reynals, Barcelona, Spain
Misconception #2:
The CAR T journey is too long for my patient to complete
Dr Samuel Yamshon
NYU Langone Health, New York, USA
Misconception #3:
The side effects of CAR T are too severe
Dr Birte Friedrichs
University Hospital Düsseldorf, Düsseldorf, Germany
Audience Q&A
All faculty, facilitated by Dr Anna Sureda
Conclusion and closing remarks
Dr Anna Sureda
Kite Publications
| # | Study | Title | Author List | Presentation Information |
|---|---|---|---|---|
|
1
|
Patient characteristics England
|
Patient characteristics in a DLBCL cohort receiving axicabtagene ciloleucel in England: a real-world feasibility study
|
ePoster presentation
Sunday, March 22, 08:30 – 18:00 |
|
|
2
|
HCRU Axi-cel England
|
Healthcare resource utilisation of patients with DLBCL receiving axicabtagene ciloleucel in England: a feasibility study
|
ePoster presentation
Sunday, March 22, 08:30 – 18:00 |
|
|
3
|
Eco benefit CAR T Spain
|
The economic benefit for patients and caregivers of expanding CAR-T centres in Spain
|
ePoster presentation
Sunday, March 22, 08:30 – 18:00 |
Our Congress Presence in 2026
On-Demand Symposia Presentations
Age is not a barrier: The older patient with comorbidities
Timing is of the essence: The patient with MCL on a BTKi
HCP Check with options
Select an option below that best describes your role to tailor the content you see: